```
elcome to STN International!  Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 31   IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                   IPC display formats
 NEWS  3  MAR 31   CAS REGISTRY enhanced with additional experimental
                   spectra
 NEWS  4  MAR 31   CA/CAplus and CASREACT patent number format for U.S.
                   applications updated
 NEWS  5  MAR 31   LPCI now available as a replacement to LDPCI
 NEWS  6  MAR 31   EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS  7  APR 04   STN AnaVist, Version 1, to be discontinued
 NEWS  8  APR 15   WPIDS, WPINDEX, and WPIX enhanced with new
                   predefined hit display formats
 NEWS  9  APR 28   EMBASE Controlled Term thesaurus enhanced
 NEWS 10  APR 28   IMSRESEARCH reloaded with enhancements
 NEWS 11  MAY 30   INPAFAMDB now available on STN for patent family
                   searching
 NEWS 12  MAY 30   DGENE, PCTGEN, and USGENE enhanced with new homology
                   sequence search option
 NEWS 13  JUN 06   EPFULL enhanced with 260,000 English abstracts
 NEWS 14  JUN 06   KOREAPAT updated with 41,000 documents
 NEWS 15  JUN 13   USPATFULL and USPAT2 updated with 11-character
                   patent numbers for U.S. applications
 NEWS 16  JUN 19   CAS REGISTRY includes selected substances from
                   web-based collections
 NEWS 17  JUN 25   CA/CAplus and USPAT databases updated with IPC
                   reclassification data
 NEWS 18  JUN 30   AEROSPACE enhanced with more than 1 million U.S.
                   patent records
 NEWS 19  JUN 30   EMBASE, EMBAL, and LEMBASE updated with additional
                   options to display authors and affiliated
                   organizations
 NEWS 20  JUN 30   STN on the Web enhanced with new STN AnaVist
                   Assistant and BLAST plug-in
 NEWS 21  JUN 30   STN AnaVist enhanced with database content from EPFULL
 NEWS 22  JUL 28   CA/CAplus patent coverage enhanced
 NEWS 23  JUL 28   EPFULL enhanced with additional legal status
                   information from the epoline Register
 NEWS 24  JUL 28   IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
 NEWS 25  JUL 28   STN Viewer performance improved
 NEWS 26  AUG 01   INPADOCDB and INPAFAMDB coverage enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:42:48 ON 05 AUG 2008

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'CAPLUS' ENTERED AT 09:45:03 ON 05 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 4 Aug 2008 (20080804/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> E THEOBALD FRANK/AU 25

E1	72		THEOBALD FRANCOIS/AU
E2	3		THEOBALD FRANCOIS R/AU
E3	30	-->	THEOBALD FRANK/AU
E4	1		THEOBALD FRANZ/AU
E5	1		THEOBALD FRED V/AU
E6	1		THEOBALD FURST/AU
E7	23		THEOBALD G/AU
E8	10		THEOBALD G W/AU
E9	10		THEOBALD GENEVIEVE/AU
E10	5		THEOBALD H/AU
E11	15		THEOBALD H MICHAEL/AU
E12	2		THEOBALD HANNAH E/AU
E13	91		THEOBALD HANS/AU
E14	1		THEOBALD HANS DR/AU
E15	1		THEOBALD HEATHER/AU
E16	2		THEOBALD HEATHER A/AU
E17	7		THEOBALD HEINZ/AU
E18	13		THEOBALD HENDRIK/AU

```
E19           1     THEOBALD HOLGER/AU
E20           1     THEOBALD I M/AU
E21           1     THEOBALD INA/AU
E22           3     THEOBALD ISABELLE/AU
E23          10     THEOBALD J/AU
E24           2     THEOBALD J A/AU
E25           1     THEOBALD J C/AU

=> S (E3)
L1           30 ("THEOBALD FRANK"/AU)

=> L1 and Transdermal
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L1 and Transdermal
         15896 TRANSDERMAL
             7 TRANSDERMALS
         15897 TRANSDERMAL
                   (TRANSDERMAL OR TRANSDERMALS)
L2           14 L1 AND TRANSDERMAL

=> s l2 and flux
        287634 FLUX
         83322 FLUXES
        328873 FLUX
                   (FLUX OR FLUXES)
L3            0 L2 AND FLUX

=> s l2 and "flux rate"
        287634 "FLUX"
         83322 "FLUXES"
        328873 "FLUX"
                   ("FLUX" OR "FLUXES")
       1960780 "RATE"
        651577 "RATES"
       2339673 "RATE"
                   ("RATE" OR "RATES")
          2379 "FLUX RATE"
                   ("FLUX"(W)"RATE")
L4            0 L2 AND "FLUX RATE"

=> d L2 1-14 ibib

L2   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:525460  CAPLUS
DOCUMENT NUMBER:          148:479897
TITLE:                    Transdermal therapeutic system containing
                          norelgestromin for contraception and hormone
                          substitution
INVENTOR(S):              Theobald, Frank; Eifler, Rene
PATENT ASSIGNEE(S):       LTS Lohmann Therapie-Systeme AG, Germany
SOURCE:                   Ger. Offen., 7pp.
                          CODEN: GWXXBX
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102006050558	A1	20080430	DE 2006-102006050558	20061026
WO 2008049516	A2	20080502	WO 2007-EP8797	20071010
WO 2008049516	A3	20080619		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: DE 2006-102006050558A 20061026

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:609363 CAPLUS

DOCUMENT NUMBER: 147:39157

TITLE: Transdermal therapeutic systems providing specific plasma concentrations of active ingredients, such as cholinesterase inhibitors

INVENTOR(S): Gargiulo, Paul M.; Lane, Roger Michael; Wall, Bettina; Platt, Beatrix; Theobald, Frank

PATENT ASSIGNEE(S): Novartis AG, Switz.; LTS Lohmann Therapie-Systeme AG

SOURCE: Can. Pat. Appl., 37pp.
CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2563110	A1	20070601	CA 2006-2563110	20061010
AU 2006320919	A1	20070607	AU 2006-320919	20061010
US 20070128263	A1	20070607	US 2006-539979	20061010
WO 2007064407	A1	20070607	WO 2006-US39557	20061010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-741511P P 20051201
WO 2006-US39557 W 20061010

L2 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:177878 CAPLUS

DOCUMENT NUMBER: 142:246203

TITLE: Medicament preparations for transdermal application containing active ingredient combinations for treating Parkinson's disease
INVENTOR(S): Horstmann, Michael; Theobald, Frank
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme Ag, Germany
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018619	A1	20050303	WO 2004-EP9136	20040814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10338174	A1	20050324	DE 2003-10338174	20030820
AU 2004266063	A1	20050303	AU 2004-266063	20040814
CA 2535063	A1	20050303	CA 2004-2535063	20040814
EP 1656122	A1	20060517	EP 2004-764129	20040814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004012054	A	20060815	BR 2004-12054	20040814
CN 1832732	A	20060913	CN 2004-80022549	20040814
JP 2007502795	T	20070215	JP 2006-523588	20040814
ZA 2005009779	A	20060927	ZA 2005-9779	20051202
IN 2006DN00717	A	20070817	IN 2006-DN717	20060213
MX 2006PA01815	A	20060531	MX 2006-PA1815	20060215
US 20070026054	A1	20070201	US 2006-568941	20060221

PRIORITY APPLN. INFO.: DE 2003-10338174 A 20030820
WO 2004-EP9136 W 20040814
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:158527 CAPLUS
DOCUMENT NUMBER: 142:225829
TITLE: Dermal or transdermal therapeutic system comprising an ormocer with barrier effect on a cover foil
INVENTOR(S): Theobald, Frank; Weber, Notger; Simon, Guenter; Amberg-Schwab, Sabine; Weber, Ulrike
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme A.-G., Germany
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005016320		A1	20050224	WO 2004-EP8221	20040723
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004028415		A1	20050303	DE 2004-102004028415	20040611
DE 102004028415		B4	20050811		
EP 1653933		A1	20060510	EP 2004-763415	20040723
EP 1653933		B1	20061108		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
AT 344660		T	20061115	AT 2004-763415	20040723
JP 2007501768		T	20070201	JP 2006-522271	20040723
ES 2275234		T3	20070601	ES 2004-763415	20040723
US 20060210615		A1	20060921	US 2006-567077	20060203
PRIORITY APPLN. INFO.:				DE 2003-10336211 A	20030807
				DE 2004-102004028415A	20040611
				WO 2004-EP8221 W	20040723

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:120738 CAPLUS
DOCUMENT NUMBER: 142:183515
TITLE: Transdermal therapeutic system with sustained release of pramipexole
INVENTOR(S): Theobald, Frank; Laux, Wolfgang; Platt, Beatrix; Kaufmann, Regine
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme AG, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011687	A1	20050210	WO 2004-EP7770	20040714
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10333393	A1	20050224	DE 2003-10333393	20030723
AU 2004260583	A1	20050210	AU 2004-260583	20040714

CA 2532904	A1	20050210	CA 2004-2532904		20040714
EP 1651215	A1	20060503	EP 2004-740987		20040714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1826113	A	20060830	CN 2004-80021039		20040714
BR 2004012240	A	20060912	BR 2004-12240		20040714
JP 2006528144	T	20061214	JP 2006-520736		20040714
US 20060182791	A1	20060817	US 2006-564932		20060113
MX 2006PA00779	A	20060711	MX 2006-PA779		20060120
PRIORITY APPLN. INFO.:			DE 2003-10333393	A	20030723
			WO 2004-EP7770	W	20040714

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:605450 CAPLUS
DOCUMENT NUMBER: 141:134119
TITLE: Method using phenylcarbamate compounds for prophylaxis against cholinesterase inhibitor poisoning, and suitable active substances and medicaments
INVENTOR(S): Becher, Frank; Hille, Thomas; Theobald, Frank ; Levy, Aharon
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme AG, Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 10301851	A1	20040729	DE 2003-10301851		20030117
WO 2004064829	A1	20040805	WO 2004-EP289		20040116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA					
EP 1585514	A1	20051019	EP 2004-702672		20040116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2004006580	A	20051220	BR 2004-6580		20040116
CN 1741800	A	20060301	CN 2004-80002412		20040116
JP 2006516267	T	20060629	JP 2005-516402		20040116
US 20060183796	A1	20060817	US 2005-542515		20050718
PRIORITY APPLN. INFO.:			DE 2003-10301851	A	20030117
			WO 2004-EP289	W	20040116

OTHER SOURCE(S): MARPAT 141:134119

L2 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:454098 CAPLUS
DOCUMENT NUMBER: 139:41793
TITLE: Transdermal therapeutic systems containing steroid hormones and propyleneglycol monocaprylate as permeation enhancer
INVENTOR(S): Theobald, Frank; Eifler, Rene
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme Ag, Germany
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047555	A1	20030612	WO 2002-EP12873	20021116
W: AU, BR, CA, CN, CZ, HU, IL, IN, JP, KR, MX, NZ, PH, PL, RU, US, ZA				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
DE 10159120	A1	20030612	DE 2001-10159120	20011201
DE 10159120	B4	20060817		
CA 2465395	A1	20030612	CA 2002-2465395	20021116
AU 2002365624	A1	20030617	AU 2002-365624	20021116
AU 2002365624	B2	20071122		
EP 1448175	A1	20040825	EP 2002-790390	20021116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				
BR 2002014634	A	20041103	BR 2002-14634	20021116
HU 2004002213	A2	20050228	HU 2004-2213	20021116
CN 1596105	A	20050316	CN 2002-823905	20021116
JP 2005531493	T	20051020	JP 2003-548811	20021116
NZ 533159	A	20051223	NZ 2002-533159	20021116
RU 2317813	C2	20080227	RU 2004-120067	20021116
ZA 2004003658	A	20040901	ZA 2004-3658	20040513
US 20050118244	A1	20050602	US 2004-497057	20040528
MX 2004PA05211	A	20040819	MX 2004-PA5211	20040531

PRIORITY APPLN. INFO.: DE 2001-10159120 A 20011201
WO 2002-EP12873 W 20021116

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:173409 CAPLUS
DOCUMENT NUMBER: 138:226720
TITLE: Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups for the use with steroid hormones and other drugs
INVENTOR(S): Klein, Robert-Peter; Hille, Thomas; Theobald, Frank
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme AG, Germany; Klein, Ursula, Hildegard
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003017988	A1	20030306	WO 2002-EP9057	20020813
W: AU, BR, CA, CN, JP, KR, MX, US, ZA				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
DE 10141652	A1	20030313	DE 2001-10141652	20010824
CA 2455064	A1	20030306	CA 2002-2455064	20020813
AU 2002327831	A1	20030310	AU 2002-327831	20020813
AU 2002327831	B2	20071025		
EP 1418895	A1	20040519	EP 2002-762444	20020813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI, CY, TR, BG, CZ, EE, SK

BR 2002011993	A	20040928	BR 2002-11993		20020813
CN 1545408	A	20041110	CN 2002-816438		20020813
JP 2005503390	T	20050203	JP 2003-522508		20020813
ZA 2004000312	A	20041101	ZA 2004-312		20040115
US 20040241219	A1	20041202	US 2004-487380		20040220
MX 2004PA01677	A	20040531	MX 2004-PA1677		20040223
HK 1069533	A1	20060804	HK 2005-102131		20050311
PRIORITY APPLN. INFO.:			DE 2001-10141652	A	20010824
			WO 2002-EP9057	W	20020813

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:657938 CAPLUS
DOCUMENT NUMBER: 137:190753
TITLE: Transdermal therapeutic system containing testosterone and method for the production
INVENTOR(S): Theobald, Frank
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme A.-G., Germany
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066018	A2	20020829	WO 2002-EP1258	20020207
WO 2002066018	A3	20030424		
W: AU, BR, CA, CN, JP, KR, MX, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
DE 10107663	A1	20020905	DE 2001-10107663	20010219
DE 10107663	B4	20040909		
CA 2438657	A1	20020829	CA 2002-2438657	20020207
AU 2002247690	A1	20020904	AU 2002-247690	20020207
AU 2002247690	B2	20060622		
EP 1361869	A2	20031119	EP 2002-716736	20020207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004517965	T	20040617	JP 2002-565578	20020207
CN 1717239	A	20060104	CN 2002-805174	20020207
KR 787545	B1	20071221	KR 2003-710810	20030818
US 20040120994	A1	20040624	US 2004-468436	20040106
PRIORITY APPLN. INFO.:			DE 2001-10107663 A	20010219
			WO 2002-EP1258 W	20020207

L2 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:397282 CAPLUS
DOCUMENT NUMBER: 138:78418
TITLE: Photoacoustic investigations on the penetration of drugs from transdermal therapeutic systems through human skin
AUTHOR(S): Beckmann, Dieter; Lauckner, Gerald; Schmidt, Kai; Asmussen, Bodo; Horstmann, Michael; Koch, Andreas; Theobald, Frank
CORPORATE SOURCE: Institut fur Bioprozess- und Analysenmesstechnik e.V., Heiligenstadt, Germany
SOURCE: Pharmazeutische Industrie (2002), 64(3), 271-277

CODEN: PHINAN; ISSN: 0031-711X
PUBLISHER: Editio Cantor Verlag
DOCUMENT TYPE: Journal
LANGUAGE: German
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:363402 CAPLUS
TITLE: Primary packaging for transdermal therapeutic systems or medical plasters
INVENTOR(S): Theobald, Frank; Laux, Wolfgang
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme Ag, Germany
SOURCE: PCT Int. Appl.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038138	A2	20020516	WO 2001-EP12618	20011031
WO 2002038138	A3	20020801		
W: JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
DE 10056234	A1	20020529	DE 2000-10056234	20001113
PRIORITY APPLN. INFO.:			DE 2000-10056234 A	20001113

L2 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:66733 CAPLUS
DOCUMENT NUMBER: 136:107565
TITLE: Transdermal therapeutic systems with light sensitive drugs and sunscreens
INVENTOR(S): Degen, Anja; Theobald, Frank
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme A.-G., Germany
SOURCE: Ger., 6 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10053375	C1	20020124	DE 2000-10053375	20001027
WO 2002034200	A2	20020502	WO 2001-EP12068	20011018
WO 2002034200	A3	20030130		
W: JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1328259	A2	20030723	EP 2001-988570	20011018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004512286	T	20040422	JP 2002-537254	20011018
US 20040022836	A1	20040205	US 2003-415144	20030530
PRIORITY APPLN. INFO.:			DE 2000-10053375 A	20001027
			WO 2001-EP12068 W	20011018

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:794990 CAPLUS
DOCUMENT NUMBER: 135:335190
TITLE: Transdermal drug delivery system for moxonidine
INVENTOR(S): Theobald, Frank
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10019311	A1	20011031	DE 2000-10019311	20000419
WO 2001080859	A1	20011101	WO 2001-EP3937	20010406
W: JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: DE 2000-10019311 A 20000419
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:780323 CAPLUS
DOCUMENT NUMBER: 135:335142
TITLE: Transdermal or transmucosal dosage forms containing nicotine for smoking cessation
INVENTOR(S): Theobald, Frank; Frick, Ulrich
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme A.-G., Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10018834	A1	20011025	DE 2000-10018834	20000415
WO 2001080837	A2	20011101	WO 2001-EP3712	20010402
WO 2001080837	A3	20020221		
W: AU, BR, CA, CN, CZ, HU, IL, IN, JP, KR, MX, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2404581	A1	20020926	CA 2001-2404581	20010402
EP 1274405	A2	20030115	EP 2001-929488	20010402
EP 1274405	B1	20040602		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
HU 2003000048	A2	20030628	HU 2003-48	20010402
HU 2003000048	A3	20050428		
BR 2001010060	A	20030715	BR 2001-10060	20010402
JP 2004501090	T	20040115	JP 2001-577936	20010402
AT 268168	T	20040615	AT 2001-929488	20010402
ES 2220772	T3	20041216	ES 2001-929488	20010402
AU 2001256246	B2	20050303	AU 2001-256246	20010402
NZ 521155	A	20060224	NZ 2001-521155	20010402

```
     RU 2301671          C2    20070627    RU 2002-123887          20010402
     ZA 2002006758       A     20031001    ZA 2002-6758            20020823
     MX 2002PA09104      A     20030312    MX 2002-PA9104          20020918
     IN 2002DN00977      A     20050128    IN 2002-DN977           20021001
     US 20030049308      A1    20030313    US 2002-257564          20021015
     HK 1051495          A1    20041126    HK 2003-103650          20030523
PRIORITY APPLN. INFO.:                      DE 2000-10018834    A   20000415
                                            WO 2001-EP3712      W   20010402
REFERENCE COUNT:         4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s "Transdermal therapeutic systems"
         15896 "TRANSDERMAL"
             7 "TRANSDERMALS"
         15897 "TRANSDERMAL"
                ("TRANSDERMAL" OR "TRANSDERMALS")
        261814 "THERAPEUTIC"
         26060 "THERAPEUTICS"
        280938 "THERAPEUTIC"
                ("THERAPEUTIC" OR "THERAPEUTICS")
       1429181 "SYSTEMS"
             4 "SYSTEMSES"
       1429185 "SYSTEMS"
                ("SYSTEMS" OR "SYSTEMSES")
L5         197 "TRANSDERMAL THERAPEUTIC SYSTEMS"
                ("TRANSDERMAL"(W)"THERAPEUTIC"(W)"SYSTEMS")

=> s L5 and pramipexol
             4 PRAMIPEXOL
L6           0 L5 AND PRAMIPEXOL

=> s pramipexol
L7           4 PRAMIPEXOL

=> d L7 ibib ab

L7   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:94662  CAPLUS
DOCUMENT NUMBER:          148:160088
TITLE:                    Method of treating and diagnosing restless legs
                          syndrome and periodic limb movements during sleep and
                          means for carrying out the method
INVENTOR(S):              Grote, Ludger; Hedner, Jan; Stenloef, Kaj
PATENT ASSIGNEE(S):       Cereuscience AB, Swed.
SOURCE:                   PCT Int. Appl., 21pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    -------------------    --------
     WO 2008010768        A1    20080124    WO 2007-SE50479        20070629
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
```

TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: SE 2006-1564 A 20060717
AB A method of treating restless legs syndrome and/or periodic limb movements during Sleep (RLS) comprises administration of a therapeutically ED of biol. active zonisamide and a dopaminergic agent selected from dopamine agonist and dopamine turnover promoting agent including dopamine uptake inhibitor over an appropriate period of time, such as a period substantially coinciding with the period of sleep of said patient. Also disclosed is a corresponding method of treatment, the use of biol. active zonisamide and a dopaminergic agent selected from dopamine agonist and dopamine turnover promoting agent including dopamine uptake inhibitor for the manufacture of a medicament for treating RLS, and a corresponding method of manufacture Administration of pramipexol with zonisamide to a patient with RLS and periodic limb movement (PLM) resulted in an additive decrease in RLS and PLM symptoms.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d L7 2-4 ibib ab

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:504306 CAPLUS
DOCUMENT NUMBER: 145:14915
TITLE: Application of HPLC in studies of pharmaceutical substances
AUTHOR(S): Zagrodzka, Joanna
CORPORATE SOURCE: Zakl. Chem., Inst. Farm., Warsaw, 01-793, Pol.
SOURCE: Przemysl Chemiczny (2006), 85(5), 363-368
CODEN: PRCHAB; ISSN: 0033-2496
PUBLISHER: Wydawnictwo SIGMA-NOT
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Polish
AB A review. The uses of HPLC in pharmaceutical anal. for drug purity determination, quality control of synthetic intermediates and final and/or preclin. study products are discussed. Examples of HPLC use in the determination of genistein and its derivs., indoquinoline glycosides, daunosamine thioglycoside, 4-demethoxydaunomycinone (key intermediate in synthesis of idarubicin hydrochloride), and compds. occurring in synthesis of anastrozol and pramipexol are given.

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:360831 CAPLUS
DOCUMENT NUMBER: 131:14122
TITLE: Modern dopamine agonists in therapy of Parkinson syndrome
AUTHOR(S): Muller-Bohn, Thomas
CORPORATE SOURCE: Susel, Germany
SOURCE: Deutsche Apotheker Zeitung (1999), 139(21), 2116-2118
CODEN: DAZEA2; ISSN: 0011-9857
PUBLISHER: Deutscher Apotheker Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: German
AB A brief review without refs. is given on dopamine agonists in therapy of Parkinson syndrome. The advantages of modern dopamine agonists like

propinirol and pramipexol against levadopa and their neuroprotective action are discussed.

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:566646 CAPLUS
DOCUMENT NUMBER: 115:166646
ORIGINAL REFERENCE NO.: 115:28363a,28366a
TITLE: Transdermal delivery system for 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole
INVENTOR(S): Zierenberg, Bernd; Herschel, Michael; Rohr, Uwe
PATENT ASSIGNEE(S): Boehringer Ingelheim K.-G., Germany
SOURCE: Ger. Offen., 4 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3937271	A1	19910516	DE 1989-3937271	19891109
EP 428038	A2	19910522	EP 1990-121170	19901106
EP 428038	A3	19910925		
EP 428038	B1	19940720		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ES 2058725	T3	19941101	ES 1990-121170	19901106
KR 184867	B1	19990501	KR 1990-17859	19901106
CA 2029524	A1	19910510	CA 1990-2029524	19901108
CA 2029524	C	20021231		
JP 03170425	A	19910724	JP 1990-303731	19901108
JP 3034588	B2	20000417		
HU 59005	A2	19920428	HU 1990-7065	19901108
HU 206043	B	19920828		
US 5112842	A	19920512	US 1990-610870	19901108
ZA 9008953	A	19920729	ZA 1990-8953	19901108
IL 96276	A	19941128	IL 1990-96276	19901108
AU 9066508	A	19910516	AU 1990-66508	19901109
AU 635358	B2	19930318		
CZ 277718	B6	19930317	CZ 1990-5534	19901109

PRIORITY APPLN. INFO.: DE 1989-3937271 A 19891109

AB Transdermal delivery systems for the title compds. or its (-)-enantiomer (pramipexol) are used for the treatment of schizophrenia and parkinsonism (no data). Skin patches were prepared, having a reservoir of pramipexol incorporated into emulsion of polyacrylate.

=> d his

(FILE 'HOME' ENTERED AT 09:42:48 ON 05 AUG 2008)

FILE 'CAPLUS' ENTERED AT 09:45:03 ON 05 AUG 2008
E THEOBALD FRANK/AU 25
L1 30 S (E3)
L2 14 S L1 AND TRANSDERMAL
L3 0 S L2 AND FLUX
L4 0 S L2 AND "FLUX RATE"
L5 197 S "TRANSDERMAL THERAPEUTIC SYSTEMS"
L6 0 S L5 AND PRAMIPEXOL
L7 4 S PRAMIPEXOL

=> s l5 and parkinsons

```
          415 PARKINSONS
L8          0 L5 AND PARKINSONS

=> S "transdermal patch"
        15896 "TRANSDERMAL"
            7 "TRANSDERMALS"
        15897 "TRANSDERMAL"
                ("TRANSDERMAL" OR "TRANSDERMALS")
        37097 "PATCH"
        19602 "PATCHES"
        50030 "PATCH"
                ("PATCH" OR "PATCHES")
L9       1309 "TRANSDERMAL PATCH"
                ("TRANSDERMAL"(W)"PATCH")

=> s l9 and pramipexol
            4 PRAMIPEXOL
L10         0 L9 AND PRAMIPEXOL

=> s L0 and "adhesive backing"
         3369 L0
       225557 "ADHESIVE"
       141191 "ADHESIVES"
       255890 "ADHESIVE"
                ("ADHESIVE" OR "ADHESIVES")
        24577 "BACKING"
         2727 "BACKINGS"
        25507 "BACKING"
                ("BACKING" OR "BACKINGS")
          214 "ADHESIVE BACKING"
                ("ADHESIVE"(W)"BACKING")
L11         0 L0 AND "ADHESIVE BACKING"

=> s L9 and methacrylate
       233679 METHACRYLATE
        12352 METHACRYLATES
       236157 METHACRYLATE
                (METHACRYLATE OR METHACRYLATES)
L12        54 L9 AND METHACRYLATE

=> s l12 and "vinyl acetate"
       434519 "VINYL"
          605 "VINYLS"
       434695 "VINYL"
                ("VINYL" OR "VINYLS")
       570571 "ACETATE"
        30047 "ACETATES"
       582952 "ACETATE"
                ("ACETATE" OR "ACETATES")
       100255 "VINYL ACETATE"
                ("VINYL"(W)"ACETATE")
L13        12 L12 AND "VINYL ACETATE"

=> s l13 and adhesive
       225557 ADHESIVE
       141191 ADHESIVES
       255890 ADHESIVE
                (ADHESIVE OR ADHESIVES)
L14        10 L13 AND ADHESIVE

=> d l14 1-10 ibib ab
```

L14 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:398409 CAPLUS
DOCUMENT NUMBER: 148:434116
TITLE: Application of medicinal composition containing rotigotine in transdermal patch
INVENTOR(S): Wang, Shuming; Xue, Huiyong; Wang, Li; Zhang, Enhong; Lian, Hongjun; Shi, Xiaoyan; Chi, Guohua; Lu, Yucheng; Liu, Xiquan; Song, Li; Zhong, Xuying; Du, Hongguang
PATENT ASSIGNEE(S): Beijing Kangbeide Pharmaceuticals Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 18pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101147739	A	20080326	CN 2007-10118491	20070706

PRIORITY APPLN. INFO.: CN 2007-10118491 20070706
AB The title medicinal composition is composed of (by%): rotigotine alkali or its pharmaceutically acceptable salt 1-40, acrylic pressure-sensitive adhesive 1-25, siloxane pressure-sensitive adhesive 65-98, and PVP 1-10. The composition can also contain dermal penetration enhancer and antioxidant. The composition can be used to prepare transdermal patch, which contains at least a backing support layer, a storage layer for rotigotine, and a protective layer.

L14 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:210965 CAPLUS
DOCUMENT NUMBER: 148:479760
TITLE: Multilayered transdermal preparation containing nonsteroidal anti-inflammatory analgesics
INVENTOR(S): Ki, Han Moe; Choi, Yang Gyu; Ah, Yeong Chang; Kim, Jeong Ju
PATENT ASSIGNEE(S): Amorepacific Corp., S. Korea; Pacific Pharma Corp.
SOURCE: Repub. Korean Kongkae Taeho Kongbo, 11pp. CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2008006961	A	20080117	KR 2006-66357	20060714

PRIORITY APPLN. INFO.: KR 2006-66357 20060714
AB The title transdermal preparation with a laminated structure comprises a supporting layer with elasticity as the upmost layer; a hydrophobic adhesive layer laminated under the supporting layer containing a hydrophobic adhesive and used for preventing the loss of water absorbed from the skin and the reverse migration of drugs; and a drug-containing adhesive layer laminated under the hydrophobic adhesive layer. The transdermal preparation provides a sealing effect via the hydrophobic adhesive layer and promotes drug absorption. The product is prepared by a simple process with reduced cost and time.

L14 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:530573 CAPLUS

DOCUMENT NUMBER: 139:219146
TITLE: Acrylate-based pressure sensitive adhesive in fabrication of transdermal therapeutic system
AUTHOR(S): Tipre, Dnyanesh N.; Vavia, Pradeep R.
CORPORATE SOURCE: University Department of Chemical Technology, Pharmaceutical Division, University of Mumbai, Mumbai, 400 019, India
SOURCE: Polymers for Advanced Technologies (2003), 14(7), 502-507
CODEN: PADTE5; ISSN: 1042-7147
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An acrylate-based pressure sensitive adhesive (PSA) was synthesized to incorporate in a design of a drug-in-adhesive (DIA) type transdermal therapeutic system (TTS) for nitrendipine and nicorandil in treatment of hypertension and angina pectoris, resp. Solns. of 2-ethylhexyl acrylate (EHA; 85% weight/weight), Me methacrylate (MMA; 10; weight/weight), acrylic acid (AA; 3% weight/weight) and vinyl acetate (VA; 2% weight/weight) in either Et acetate, acetone or methanol were polymerized under free radical conditions to synthesize the PSA. The effects of solvent, reaction time, initiator concentration and reaction temperature on polymerization were studied. The resultant copolymers were characterized by 1H-NMR, IR, differential scanning calorimetry (DSC) and gel permeation chromatog. (GPC) and the intrinsic viscosities, refractive index, peel strength, moisture uptake and skin irritation potential were determined The PSA was used to develop DIA type patches for delivery of nitrendipine and nicorandil. The TTS were evaluated for thickness, weight, peel strength, moisture uptake, in vitro release and in vitro skin permeation through guinea-pig skin. The copolymer found to effectively control the rate of drug release and the corresponding TTSs could be successfully employed in transdermal delivery of nitrendipine and nicorandil.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:802791 CAPLUS
DOCUMENT NUMBER: 132:26879
TITLE: Transdermal patches containing vasodilators
INVENTOR(S): Yamamoto, Tatsuo; Utagawa, Hiroko
PATENT ASSIGNEE(S): Sekisui Chemical Co. Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11349477	A	19991221	JP 1998-157641	19980605

PRIORITY APPLN. INFO.: JP 1998-157641 19980605

AB Transdermal drug patches for long-lasting effects without causing itch, comprise vasodilators 0.1-30 % and antipruritic substances 0.1-15 % in a hydrophilic polymer base. Isosorbide nitrate 15 g and crotamiton 10 g were added to 209.7 g of 2-ethylhexyl acrylate-hexamethylene glycol methacrylate-vinylpyrrolidone copolymer dissolved in EtOAc. The mixture was applied onto a polyester film and dried. The resulting film was laminated on a polyethylene terephthalate/ethylene-vinyl

acetate film to give a tape.

L14 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:414876 CAPLUS
DOCUMENT NUMBER: 129:72227
ORIGINAL REFERENCE NO.: 129:14875a,14878a
TITLE: Transdermal drug delivery system for the treatment of heart diseases
INVENTOR(S): Cordes, Gunter; Santoro, Antonino; Setnikar, Ivo
PATENT ASSIGNEE(S): Rotta Research B.V., Neth.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825591	A1	19980618	WO 1997-EP6892	19971210
W: BG, CZ, HU, KR, MX, PL, RO, RU, SI, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 856311	A1	19980805	EP 1996-119801	19961210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 944384	A1	19990929	EP 1997-952048	19971210
EP 944384	B1	20020313		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
AT 214271	T	20020315	AT 1997-952048	19971210
PT 944384	T	20020628	PT 1997-952048	19971210
ES 2138945	T3	20021001	ES 1997-952048	19971210
PRIORITY APPLN. INFO.:			EP 1996-119801 A	19961210
			WO 1997-EP6892 W	19971210

AB The invention concerns a transdermal drug delivery system for the delivery of nitroglycerin (NG) to humans, which comprises the following three layers: (1) a drug-free backing layer; (2) an optionally crosslinked acrylic adhesive layer having a content of NG and optionally a tackifying agent; and (3) an optionally crosslinked acrylic adhesive layer having a content of NG and a tackifying agent; and, in addition, a release liner. A sheet prepared from a mixture containing 2-ethylhexyl acrylate-glycidyl methacrylate-hydroxyethyl acrylate-vinyl acetate copolymer 83.67, polybutyl titanate 0.61, Celolyn 21E 3, and NG 20 kg and a sheet prepared from a mixture containing 2-ethylhexyl acrylate-glycidyl methacrylate-hydroxyethyl acrylate-vinyl acetate copolymer 22.35, polybutyl titanate 0.072, Celolyn 21E 0.31, and NG 5 kg were pressed against each other to give a laminate composed of a backing foil.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:135893 CAPLUS
DOCUMENT NUMBER: 128:248614
ORIGINAL REFERENCE NO.: 128:49133a,49136a
TITLE: Pressure-sensitive medical adhesive compositions containing acrylic copolymers and aliphatic alcohols
INVENTOR(S): Udagawa, Hiroko
PATENT ASSIGNEE(S): Sekisui Chemical Co. Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10057468	A	19980303	JP 1996-221283	19960822
JP 3792305	B2	20060705		

PRIORITY APPLN. INFO.: JP 1996-221283 19960822

AB The compns. contain 80-99.5 weight% copolymers of 2-ethylhexyl methacrylate (I) with C6-16 alkyl (meth)acrylate, where content of I is 40-90 weight%, and 0.5-20 weight% aliphatic alcs. The compns. show low skin-irritating action. A PET film was coated with a composition containing dodecyl methacrylate-2-ethylhexyl methacrylate -2-ethylhexyl acrylate-hexanediol dimethacrylate copolymer (preparation given), indomethacin, cetyl alc., iso-Pr myristate, SiO2, and AcOEt, and the adhesive layer was supported on a polyester/ethylene-vinyl acetate copolymer film to give a transdermal patch with low skin irritation.

L14 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:134863 CAPLUS
DOCUMENT NUMBER: 126:148516
ORIGINAL REFERENCE NO.: 126:28651a
TITLE: Transdermal patches comprising pressure-sensitive polyacrylate adhesive crosslinked with aluminum acetylacetonate and a drug having a reactive aromatic hydroxyl group
INVENTOR(S): Li, Chunhua; Schonfeld, Edward; Chu, Tara; Chiang, Chia-Ming
PATENT ASSIGNEE(S): Cygnus, Inc., USA
SOURCE: PCT Int. Appl., 8 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640087	A2	19961219	WO 1996-US8492	19960603
WO 9640087	A3	19970130		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML

AU 9660326	A	19961230	AU 1996-60326	19960603

PRIORITY APPLN. INFO.: US 1995-484294 A 19950607
WO 1996-US8492 W 19960603

AB Non-yellowing organic solvent-based pressure-sensitive polyacrylate adhesives which have good cohesive strength and cold flow properties and are useful in fabricating transdermal drug delivery patches, are made from an polyacrylate crosslinked with aluminum acetylacetonate (I) and combined with a drug, such as estradiol, that has a reactive aromatic hydroxyl group. Duro-tak 87-2287 (2-ethylhexyl acrylate-glycidyl methacrylate-hydroxyethyl acrylate-vinyl acetate copolymer) was mixed with I and 17β-estradiol. The mixture was cured at 900° for 2 min and cast

onto a release liner. A transdermal patch was obtained by assembly with a backing layer and skin flux tests were carried out. The adhesive layer of the patch remained uncolored after storage at 450° for 3 mo.

L14 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:517704 CAPLUS
DOCUMENT NUMBER: 121:117704
ORIGINAL REFERENCE NO.: 121:21085a,21088a
TITLE: Transdermal therapeutic system for administration of physostigmine to the skin, and its manufacture
INVENTOR(S): Deurer, Lothar; Hille, Thomas; Profitlch, Thomas; Stanislaus, Fritz; Walter, Kersten
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme GmbH und Co. KG, Germany; Klinge Pharma GmbH
SOURCE: Ger., 10 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4238223	C1	19940526	DE 1992-4238223	19921112
CA 2147274	A1	19940526	CA 1993-2147274	19931027
CA 2147274	C	20051213		
WO 9410999	A1	19940526	WO 1993-EP2970	19931027
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9453385	A	19940608	AU 1994-53385	19931027
AU 684256	B2	19971211		
EP 667774	A1	19950823	EP 1993-923558	19931027
EP 667774	B1	19970806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08502986	T	19960402	JP 1994-511649	19931027
JP 3407073	B2	20030519		
HU 72963	A2	19960628	HU 1995-1390	19931027
AT 156356	T	19970815	AT 1993-923558	19931027
ES 2105334	T3	19971016	ES 1993-923558	19931027
PL 172999	B1	19980130	PL 1993-308531	19931027
RU 2108812	C1	19980420	RU 1995-113504	19931027
CZ 284008	B6	19980715	CZ 1995-1244	19931027
SK 280185	B6	19990910	SK 1995-593	19931027
LV 10749	B	19960620	LV 1993-1204	19931105
IL 107547	A	19961205	IL 1993-107547	19931109
ZA 9308413	A	19940609	ZA 1993-8413	19931111
CN 1088457	A	19940629	CN 1993-112909	19931111
LT 3107	B	19941227	LT 1993-1469	19931112
FI 9502269	A	19950510	FI 1995-2269	19950510
NO 9501864	A	19950511	NO 1995-1864	19950511
NO 306760	B1	19991220		

PRIORITY APPLN. INFO.: DE 1992-4238223 A 19921112
WO 1993-EP2970 W 19931027

AB The title transdermal dosage form comprises (a) an impermeable backing layer, (b) an adhesive reservoir layer containing 40-90 weight% acrylate or methacrylate polymer material, 0.1-20 weight% physostigmine (salt), and 0.1-40 weight% OH group-containing plasticizer (HLB value 1.1-12.0), and (c) a detachable protective layer. Physostigmine is not hydrolyzed by this combination of polymer and plasticizer. Thus, a solution of 2-ethylhexyl acrylate/vinyl acetate/acrylic

acid copolymer 67, dimethylaminoethyl methacrylate/neutral methacrylate ester copolymer 10, physostigmine 8, and 1-hexanol (plasticizer) 15 parts in organic solvent was spread on an aluminized siliconized polyethylene film, dried at 60°, and covered with polyester film. The adhesive strength of the product was 9.89 N/16 cm2.

L14 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:11230 CAPLUS
DOCUMENT NUMBER: 116:11230
ORIGINAL REFERENCE NO.: 116:1983a,1986a
TITLE: Anti-inflammatory and analgesic transdermal patches containing piroxicam and acrylic adhesives
INVENTOR(S): Maeda, Minoru; Ochi, Masato; Kozen, Hiroyuki
PATENT ASSIGNEE(S): Maeda Yakuhin Kogyo Co., Ltd., Japan; Matsui Seiyaku Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03109327	A	19910509	JP 1989-244970	19890922
PRIORITY APPLN. INFO.:			JP 1989-244970	19890922

AB The title patches with good bioavailability contain piroxicam (I) and noncrosslinked acrylic polymers as adhesive bases. I 1.67, diisopropanolamine 0.83, polyethylene glycol monolaurate 1.50, and noncrosslinked Bu acrylate-methacrylic acid copolymer emulsion 186.40 g were mixed, coated on a polyethylene film, dried, and applied on a liner to give a controlled-release patch.

L14 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:141546 CAPLUS
DOCUMENT NUMBER: 110:141546
ORIGINAL REFERENCE NO.: 110:23253a,23256a
TITLE: Pharmaceutical patches containing a storage reservoir for active agents and a skin-side reservoir matrix
INVENTOR(S): Hoffmann, Annegrete
PATENT ASSIGNEE(S): Lohmann G.m.b.H. und Co. K.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 9 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3629304	A1	19880324	DE 1986-3629304	19860828
DE 3629304	C2	19890330		
WO 8801516	A1	19880310	WO 1987-DE372	19870820
W: AU, DK, FI, HU, JP, KR, NO, US				
AU 8778035	A	19880324	AU 1987-78035	19870820
AU 606885	B2	19910221		
EP 261402	A1	19880330	EP 1987-112103	19870820
EP 261402	B1	19920318		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				

JP 01503706	T	19891214	JP 1987-504765		19870820
JP 2763773	B2	19980611			
HU 56493	A2	19910930	HU 1987-4191		19870820
HU 204701	B	19920228			
AT 73677	T	19920415	AT 1987-112103		19870820
ES 2030026	T3	19921016	ES 1987-112103		19870820
DD 274975	A5	19900110	DD 1987-306381		19870826
CZ 277739	B6	19930317	CZ 1987-6237		19870826
SK 277842	B6	19950412	SK 1987-6237		19870826
ZA 8706388	A	19880427	ZA 1987-6388		19870827
CA 1312800	C	19930119	CA 1987-545583		19870827
IL 83668	A	19930513	IL 1987-83668		19870827
PL 161466	B1	19930630	PL 1987-267473		19870827
NO 173168	B	19930802	NO 1988-2136		19880516
NO 173168	C	19931110			
DK 8802700	A	19880517	DK 1988-2700		19880517
DK 175077	B1	20040524			
FI 95539	B	19951115	FI 1988-2417		19880523
FI 95539	C	19960226			
NO 9102851	A	19880628	NO 1991-2851		19910719
NO 302102	B1	19980126			
US 6110488	A	20000829	US 1995-471021		19950606
US 6117448	A	20000912	US 1995-466800		19950606
US 6126963	A	20001003	US 1995-471013		19950606
US 6224900	B1	20010501	US 1998-37140		19980309
US 6264977	B1	20010724	US 1999-428368		19991028
US 37934	E1	20021210	US 2000-498757		20000203
PRIORITY APPLN. INFO.:			DE 1986-3629304	A	19860828
			EP 1987-112103	A	19870820
			NO 1988-2136	A1	19870820
			WO 1987-DE372	A	19870820
			US 1988-219066	B1	19880627
			US 1990-597102	B1	19901012
			US 1992-908930	B3	19920708
			US 1993-27822	B1	19930507
			US 1993-27698	B1	19930517
			US 1993-27884	B1	19930517
			US 1994-319086	B2	19941006
			US 1994-341844	B2	19941118
			US 1994-344415	B2	19941123
			US 1995-469207	A3	19950606
			US 1995-471013	A1	19950606

AB A transdermal patch comprises a depot containing the active agent, a distribution device for the active agent, and an adhesive device. The distribution device comprises ≥1 sep. storage reservoirs that contain higher concns. of active agent than the skin-side reservoir. A self-adhesive composite containing 2.0825 kg self-crosslinking polymerizable mixture of 2-ethylhexyl acrylate, vinyl acetate, acrylic acid, and Ti chelate ester in a mixture of AcOEt, EtOH, hexane, and MeOH was mixed with 147 g dimethylaminomethyl methacrylate-methyacrylate copolymer (I) and 20 g C8-10 triglycerides, and this was applied to a sheet of Al foil, the solvent was evaporated and coated a bilaterally adhesive protective foil. Circular patches with 65 mm diameter were punched out of this composite and their centers were laminated with a cellulose-cotton fabric with 40 mm diameter Containers filled with a mixture of 140 g nicotine (102 mg/dose) and 100 g I were covered with these patches; this composite was coated with a nicotine-impermeable polyester-coated Al foil and packaged in paper pouches.

```
=> d his

     (FILE 'HOME' ENTERED AT 09:42:48 ON 05 AUG 2008)

     FILE 'CAPLUS' ENTERED AT 09:45:03 ON 05 AUG 2008
                E THEOBALD FRANK/AU 25
L1           30 S (E3)
L2           14 S L1 AND TRANSDERMAL
L3            0 S L2 AND FLUX
L4            0 S L2 AND "FLUX RATE"
L5          197 S "TRANSDERMAL THERAPEUTIC SYSTEMS"
L6            0 S L5 AND PRAMIPEXOL
L7            4 S PRAMIPEXOL
L8            0 S L5 AND PARKINSONS
L9         1309 S "TRANSDERMAL PATCH"
L10           0 S L9 AND PRAMIPEXOL
L11           0 S L0 AND "ADHESIVE BACKING"
L12          54 S L9 AND METHACRYLATE
L13          12 S L12 AND "VINYL ACETATE"
L14          10 S L13 AND ADHESIVE

=> s l9 and "flux rate"
        287634 "FLUX"
         83322 "FLUXES"
        328873 "FLUX"
                 ("FLUX" OR "FLUXES")
       1960780 "RATE"
        651577 "RATES"
       2339673 "RATE"
                 ("RATE" OR "RATES")
          2379 "FLUX RATE"
                 ("FLUX"(W)"RATE")
L15           7 L9 AND "FLUX RATE"

=> d L15 1-7 ibib ab

L15  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2000:799314  CAPLUS
DOCUMENT NUMBER:          134:183411
TITLE:                    Pharmaceutical development and characteristics of a
                          new glyceryl trinitrate transdermal
                          patch
AUTHOR(S):                Santoro, Antonino; Rovati, Lucio C.; Lanzini, Roberto;
                          Setnikar, Ivo
CORPORATE SOURCE:         Department of Development and Regulatory Affairs,
                          Rotta Research Laboratorium, Monza, Italy
SOURCE:                   Arzneimittel-Forschung (2000), 50(10), 897-903
                          CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER:                Editio Cantor Verlag
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB    The pharmaceutical development and characteristics of the new glyceryl
      trinitrate (GTN) transdermal patch Epinitril (EPI) are
      described.  EPI is a thin (0.096 mm), transparent patch, with GTN
      uniformly dissolved in a monolayer pressure-sensitive acrylates vinyl
      acetate copolymer adhesive matrix.  The patch provides an intense
      flux rate of GTN through the skin (33 μg/cm2/h).
      This is the result of the high concentration of GTN in the matrix (39.3%
weight/weight)
      and of its thinness (0.033 mm), which elicit a high thermodn. activity of
      GTN on the surface of the skin, promoting its absorption.  EPI was
```

developed in 3 strengths with release rates of 5, 10 and 15 mg GTN in 24 h, to allow the adaptation of the dose to the needs of the individual patient. During development, different tests were used to evaluate in vitro the release of GTN, i.e., the disk assembly dissoln. test, the artificial membrane-controlled dissoln. test and the diffusion test through the stratum corneum and epidermis of human skin. None was able to provide a reliable in vitro-in vivo correlation of the performance of the investigated patches. The tests, however, are useful to evaluate the effects of formulation changes during pharmaceutical development. For its small size, thinness, flexibility, transparency, easiness of application and of removal and for its good tolerability, EPI is very patient friendly, a quality that improves the compliance with the long-term therapeutic courses needed in angina pectoris.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:649931 CAPLUS

DOCUMENT NUMBER: 132:40406

TITLE: A therapeutic dose of primaquine can be delivered across excised human skin from simple transdermal patches

AUTHOR(S): Jeans, C. W.; Heard, C. M.

CORPORATE SOURCE: Welsh School of Pharmacy, Cardiff University, Cardiff, UK

SOURCE: International Journal of Pharmaceutics (1999), 189(1), 1-6
CODEN: IJPHDE; ISSN: 0378-5173

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This work investigated the permeation of primaquine across full-thickness excised human skin from two acrylate transdermal adhesives. Primaquine base was formulated with National Starch 387-2516 and 387-2287 to provide aluminum foil-backed 1-cm diameter patches, each loaded with 10 mg drug. Other patches were prepared that included Migliol 840 as a potential penetration enhancer. The patches were applied to cadaver skin in Franz-type diffusion cells and the permeation of primaquine determined over a 24-h period. Relatively high fluxes were found, the highest being from those formulations lacking the Miglyol 840: 5.68+10-2 mg cm-2 h-1 from 387-2516; 4.94+10-2 mg cm-2 h-1 from 387-2287. A simple patch with a diameter of ≈13 cm2 could deliver a therapeutic in vivo dose, with possibilities for the treatment and prophylaxis of Plasmodium vivax, P. ovale and P. falciparum forms of malaria. The presence of Miglyol 840 failed to produce the anticipated enhancing effect: flux rates that were approx. halved. These results could to a certain extent be rationalized in terms of thermodn. activity.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:147261 CAPLUS

DOCUMENT NUMBER: 130:187232

TITLE: Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen

INVENTOR(S): Jona, Janan; Audett, Jay; Singh, Noel

PATENT ASSIGNEE(S): Cygnus, Inc., USA

SOURCE: U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 517,263, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5876746	A	19990302	US 1996-660024	19960606
CA 2222133	A1	19961219	CA 1996-2222133	19960606
CA 2222133	C	20021224		
CN 1190351	A	19980812	CN 1996-195390	19960606
HU 9802326	A2	19990201	HU 1998-2326	19960606
HU 9802326	A3	19990728		
IL 122432	A	20000716	IL 1996-122432	19960606
PT 836506	T	20030430	PT 1996-921353	19960606
ES 2190472	T3	20030801	ES 1996-921353	19960606
CZ 292151	B6	20030813	CZ 1997-3932	19960606
US 5972377	A	19991026	US 1998-165526	19981002
JP 2004043510	A	20040212	JP 2003-376231	20031105

PRIORITY APPLN. INFO.: US 1995-473531 B2 19950607
US 1995-517263 B2 19950821
JP 1997-501723 A3 19960606
US 1996-660024 A1 19960606

AB Compns. and methods for preventing ovulation in a woman are provided, as well as compns. and methods for female hormone replacement therapy. The compns. can be administered by the use of a transdermal patch. The patch will administer 17-deacetyl norgestimate (I) alone or in combination with an estrogen such as ethinyl estradiol (II) to women via an adhesive matrix of a silicone and/or polyisobutylene. Mixts. of Duro-Tak 87-2287, 0.26% aluminum acetylacetonate crosslinker, 6% I, 1% II EE, 2% thioglycerol, and 4% oleic acid were prepared These mixts. were cured and cast as a 100 μ thick (wet) layer onto a 3M 1022 polyester backing and dried. Skin flux tests were carried out on the resulting assemblies. The flux rate for I and II was 0.30 and 0.061 μg/cm2/h, resp.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:474064 CAPLUS
DOCUMENT NUMBER: 129:127176
ORIGINAL REFERENCE NO.: 129:25943a,25946a
TITLE: Transdermal therapeutic system
INVENTOR(S): Dittgen, Michael; Fricke, Sabine; Voelkel, Christoph; Ahrens, Kathrin; Gerecke, Hagen
PATENT ASSIGNEE(S): Jenapharm G.m.b.H. und Co. K.-G., Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19701949	A1	19980716	DE 1997-19701949	19970113
CA 2277367	A1	19980716	CA 1998-2277367	19980113
WO 9830203	A2	19980716	WO 1998-DE157	19980113
WO 9830203	A3	19990422		

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL,

RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9866078	A	19980803	AU 1998-66078	19980113
AU 740912	B2	20011115		
BR 9806747	A	20000314	BR 1998-6747	19980113
EP 1014954	A2	20000705	EP 1998-907826	19980113
EP 1014954	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
HU 2000000615	A2	20001028	HU 2000-615	19980113
HU 2000000615	A3	20010328		
NZ 336638	A	20010928	NZ 1998-336638	19980113
JP 2002512600	T	20020423	JP 1998-530471	19980113
AT 244003	T	20030715	AT 1998-907826	19980113
ES 2205455	T3	20040501	ES 1998-907826	19980113
MX 9906501	A	20000131	MX 1999-6501	19990712
US 6238284	B1	20010529	US 1999-341416	19990910
US 20010018073	A1	20010830	US 2001-801184	20010305
US 20030044453	A1	20030306	US 2002-211400	20020802

PRIORITY APPLN. INFO.:	DE 1997-19701949	A	19970113
	WO 1998-DE157	W	19980113
	US 1999-341416	A1	19990910
	US 2001-801184	A3	20010305

AB A transdermal therapeutic system for use on the skin or mucous membranes comprises an active agent in the form of a solid dispersion in an inert carrier, combined with ≥1 water structure-breaking agent and/or ≥1 water structure-reinforcing agent in a common matrix. The water structure-breaking agent is a carboxamide (e.g. urea, nicotinamide, succinamide, AcNHMe) which provides a relaxation time of >120 ms. The water structure-reinforcing agent is a polyol (e.g. glycerin, ethylene glycol, propylene glycol, sugar alc.) which provides a relaxation time of preferably <80 ms. When used in combination to provide a precise flux rate across the skin, the structure-breaking and -reinforcing agents are preferably in a ratio of (2:1)-(1:2). Thus, a 0.5% testosterone hydrogel containing testosterone 0.500, gel matrix-forming agent 0.500, solubilizer 1 (not specified) 0.500, solubilizer 2 (not specified) 46.875, and H2O to 100.00 g permeated through cow udder skin (thickness 1.2 mm) at 3.1 μg/cm2/h. Corresponding hydrogels addnl. containing nicotinamide (0.5 mol/kg), lactose (45 g/kg) as a solid dispersion, or nicotinamide + lactose showed permeation rates of 5.5, 7.4, and 11.8 μg/cm2/h, resp.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1997:790366 CAPLUS
DOCUMENT NUMBER:	128:93107
ORIGINAL REFERENCE NO.:	128:18121a,18124a
TITLE:	Percutaneous absorption and histopathology of a poloxamer-based formulation of capsaicin analog
AUTHOR(S):	Lee, Beom-Jin; Lee, Tae-Sup; Cha, Bong-Jin; Kim, Soon-Hoe; Kim, Won-Bae
CORPORATE SOURCE:	College of Pharmacy, Biological Rhythm and Controlled Release Laboratory, Kangwon National University, Chuncheon, 200-701, S. Korea
SOURCE:	International Journal of Pharmaceutics (1997), 159(1), 105-114 CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER:	Elsevier Science B.V.

DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new synthetic capsaicin analog (CA) modified with 4-hydroxyl and alkyl chain of capsaicin was synthesized as a potent anti-inflammatory analgesic drug and is now on clin. trial in Korea. The purpose of this study was to investigate the percutaneous absorption and histopathol. of a poloxamer-based formulation of CA. A poloxamer-based gel was prepared by cold method using poloxamer 407. Vertical Franz type diffusion cells were used for skin penetration of drug against receptor phase filled with about 10 mL of 0.9 isotonic saline at 32°C. The concentration of drug was determined by the reverse phased HPLC (C18, Symmetry®) with fluorometeric detector. Total amount of CA free base permeated was higher than that of the CA salt form. Percutaneous absorption of CA was greatly enhanced in ethanol and PG than that in water, 2-hydroxypropy-β-cyclodextrin and PEG400. As ethanol concentration increased, percutaneous absorption greatly increased. The flux rate of CA increased slightly when PG was added to ethanol solution The marked enhancing effect of the 5 fatty acid IPM in cosolvents was also noted on the percutaneous absorption of a poloxamer-based formulation of CA. Addition of 5 OA and 5 LA into the gel containing 5 IPM resulted in a slight increase in skin permeation. No significant difference in skin permeation was observed as a function of poloxamer content (20, 25 and 30). The buffer system of 30 poloxamer-based gel slightly changed the cumulative amts. of CA penetrated for 24 h. The flux of poloxamer-based gels increased linearly as the drug concentration increased. There was a variation of percutaneous absorption of the drug, depending on the species used. The flux of a poloxamer-based formulation of CA was the highest in case of hairless mice but the lowest in hamsters. No skin erythema and histopathol. changes were observed on the dorsal site of hairless mice in six groups after a week or two months application, suggesting no skin toxicity of the poloxamer-based gel. Based on these findings, the current poloxamer-based formulation appears useful in the systemic delivery of CA as topical or transdermal patch formulations.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:8281 CAPLUS
DOCUMENT NUMBER: 124:97443
ORIGINAL REFERENCE NO.: 124:18017a,18020a
TITLE: Kinetics of a novel patch for transdermal application of 17-β-estradiol
AUTHOR(S): Rohr, U. D.; Nauert, C.; Ehrly, A. M.
CORPORATE SOURCE: Zentrum fur Innere Medizin, Medizinische Klinik I, Schwerpunkt, Germany
SOURCE: Zentralblatt fuer Gynaekologie (1995), 117(10), 531-9
CODEN: ZEGYAX; ISSN: 0044-4197
PUBLISHER: Barth
DOCUMENT TYPE: Journal
LANGUAGE: German
AB A novel patch containing 17-β-estradiol (I) exhibits improved kinetic profiles compared to the currently available leading transdermal product. The blood concns. produced by the newly developed matrix patch are stable over 3 to 4 days, thus avoiding the occurrence of I peaks in the blood. In an addnl. clin. study an almost linear relation was identified between the patch size (test patch: 7.25, 14.5 and 29.0 cm2) and the I bioavailability (based on AUC, cmax, cave, cmin). These results are corroborated by the addnl. in vitro expts. An almost constant drug delivery rate of 48 μg/day of I per 13.85 cm2 patch over 4 days can be detected through excised human skin. No statistically significantly different

transdermal flux rates of I were detected in 3 different batches of the transdermal drug delivery system in vitro. Statistical evaluations were performed with the 3-way-Anova test on the 0.05 significance level. This newly developed product presents a kinetically optimized transdermal I patch for hormone substitution therapy.

L15 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:118973 CAPLUS
DOCUMENT NUMBER: 108:118973
ORIGINAL REFERENCE NO.: 108:19401a,19404a
TITLE: Transdermal controlled-release patch containing a vasoactive substance, silicone rubber, and a cellulose derivative
INVENTOR(S): Kim, Benjamin K.
PATENT ASSIGNEE(S): Paco Research Corp., USA
SOURCE: Pat. Specif. (Aust.), 20 pp.
CODEN: ALXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 561608	B1	19870514	AU 1986-60267	19860717
EP 224981	A2	19870610	EP 1986-305511	19860717
EP 224981	A3	19880810		
R: BE, DE, FR, GB, IT, LU, NL, SE				
ES 2001064	A6	19880416	ES 1986-878	19860805
JP 62108812	A	19870520	JP 1986-230200	19860930

PRIORITY APPLN. INFO.: US 1985-795047 A 19851104

AB A transdermal delivery system for vasoactive substances contains a liquid silicone rubber 30-70, a vasoactive substance 5-25, a gelling agent 0.1-2.0, a material which swells as water is absorbed from the stratum corneum 2-15, and a mixture containing solvents, viscosity reducers, and skin penetration enhancers 5-35% by weight A polymer matrix was prepared by curing a mixture containing 10% nitroglycerin on lactose 11, iso-Pr myristate 15, dodecyl alc. 6, liquid silicone rubber 27, colloidal SiO2 1, and Na starch glycollate 7 g at 60° for 2.5 h. In a Franz cell assay the above composition was applied to the excised skin of hairless mice which was mounted between the compartments of a diffusion cell. The average flux rate for nitroglycerin was 27.244 μg/h/cm2. The patches are stored in sealed Al pouches until use.

=> d his

(FILE 'HOME' ENTERED AT 09:42:48 ON 05 AUG 2008)

FILE 'CAPLUS' ENTERED AT 09:45:03 ON 05 AUG 2008
E THEOBALD FRANK/AU 25
L1 30 S (E3)
L2 14 S L1 AND TRANSDERMAL
L3 0 S L2 AND FLUX
L4 0 S L2 AND "FLUX RATE"
L5 197 S "TRANSDERMAL THERAPEUTIC SYSTEMS"
L6 0 S L5 AND PRAMIPEXOL
L7 4 S PRAMIPEXOL
L8 0 S L5 AND PARKINSONS
L9 1309 S "TRANSDERMAL PATCH"

```
L10           0 S L9 AND PRAMIPEXOL
L11           0 S L0 AND "ADHESIVE BACKING"
L12          54 S L9 AND METHACRYLATE
L13          12 S L12 AND "VINYL ACETATE"
L14          10 S L13 AND ADHESIVE
L15           7 S L9 AND "FLUX RATE"

=> s "dopamine agonist"
         93866 "DOPAMINE"
            99 "DOPAMINES"
         93887 "DOPAMINE"
                 ("DOPAMINE" OR "DOPAMINES")
        119853 "AGONIST"
         90247 "AGONISTS"
        164010 "AGONIST"
                 ("AGONIST" OR "AGONISTS")
L16       6224 "DOPAMINE AGONIST"
                 ("DOPAMINE"(W)"AGONIST")

=> s L9 and L16
L17          16 L9 AND L16

=> s L17 and @py<=2003
'2003' NOT A VALID FIELD CODE
             0 @PY<=2003
L18          0 L17 AND @PY<=2003

=> S L17 AND PY<=2003
      24005665 PY<=2003
L19          6 L17 AND PY<=2003

=> d L19 1-6 ibib ab

L19  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2003:818867  CAPLUS
DOCUMENT NUMBER:          139:332184
TITLE:                    Rotigotine Schwarz Pharma
AUTHOR(S):                Mucke, Hermann A. M.
CORPORATE SOURCE:         HM Pharma Consultancy, Vienna, A-1160, Austria
SOURCE:                   IDrugs (2003), 6(9), 894-899
                          CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER:                Current Drugs
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 English
AB   A review.  Schwarz Pharma AG, under license from Aderis Pharmaceuticals
     Inc, is developing rotigotine CDS, a once-daily transdermal
     patch formulation of rotigotine, which is a naphthol-derived
     selective D2 dopamine agonist, for the potential
     treatment of Parkinson's disease and restless legs syndrome.
REFERENCE COUNT:          34    THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19  ANSWER 2 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2003:492711  CAPLUS
DOCUMENT NUMBER:          139:57970
TITLE:                    Methods and compositions for regulating memory
                          consolidation
INVENTOR(S):              Epstein, Mel H.; Wiig, Kjesten A.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S.
                          Ser. No. 3,740.
```

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030119884	A1	20030626	US 2002-139606	20020502 <--
WO 2002039998	A2	20020523	WO 2001-US45793	20011031 <--
WO 2002039998	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020115725	A1	20020822	US 2001-3740	20011031 <--
US 6828351	B2	20041207		
EP 1743631	A2	20070117	EP 2006-20373	20011031
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
US 20030232890	A1	20031218	US 2003-444970	20030523 <--
US 20050059743	A1	20050317	US 2004-791223	20040302
WO 2005000203	A2	20050106	WO 2004-US15974	20040521
WO 2005000203	A3	20051229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20060111448	A1	20060525	US 2005-133144	20050519
US 20060167111	A1	20060727	US 2005-303633	20051215
US 7244769	B2	20070717		
US 20060167112	A1	20060727	US 2005-305495	20051215
US 20070117869	A1	20070524	US 2006-557095	20060303
US 20070099999	A1	20070503	US 2006-636644	20061208
US 20070100000	A1	20070503	US 2006-636702	20061208
US 20070197663	A1	20070823	US 2006-636703	20061208

PRIORITY APPLN. INFO.:

US 2000-245323P	P	20001101
US 2001-3740	A2	20011031
WO 2001-US45793	A	20011031
EP 2001-987226	A3	20011031
US 2002-139606	A2	20020502
US 2003-444970	A2	20030523
US 2003-473168P	P	20030523
US 2004-791223	A2	20040302
WO 2004-US15974	A2	20040521
US 2006-557095	A1	20060303

OTHER SOURCE(S): MARPAT 139:57970

AB The present invention makes available methods and reagents for enhancing

and/or restoring long-term memory function and performance. A pharmaceutical kit comprising one or more amphetamine compds. in an amount sufficient to enhance long-term memory in a patient, a pharmaceutically acceptable carrier, and instructions describing the use for the formulation for enhancing memory are disclosed.

L19 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:332037 CAPLUS
DOCUMENT NUMBER: 136:330587
TITLE: Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
INVENTOR(S): Horowski, Reinhard; Tack, Johannes
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034267	A1	20020502	WO 2001-EP9826	20010824 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10053397	A1	20020502	DE 2000-10053397	20001020 <--
AU 2001095512	A	20020506	AU 2001-95512	20010824 <--
EP 1303278	A1	20030423	EP 2001-976150	20010824 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004512305	T	20040422	JP 2002-537318	20010824
AU 2001295512	B2	20060921	AU 2001-295512	20010824
US 20040092544	A1	20040513	US 2003-362182	20030703
US 7258871	B2	20070821		
US 20060105030	A1	20060518	US 2005-87754	20050324
US 20070243240	A9	20071018		
US 20050214353	A1	20050929	US 2005-116278	20050428
US 20050220855	A1	20051006	US 2005-116279	20050428

PRIORITY APPLN. INFO.:		
DE 2000-10053397	A	20001020
DE 2000-10043321	A	20000824
WO 2001-EP9823	W	20010824
WO 2001-EP9824	W	20010824
WO 2001-EP9826	W	20010824
US 2003-362182	A2	20030703
US 2003-362248	A2	20030707
US 2003-362183	A2	20030721
DE 2003-10341317	A	20030903
WO 2004-DE1133	A2	20040530

OTHER SOURCE(S): MARPAT 136:330587
AB The invention relates to the use of a dopamine agonist in the form of an agent, comprising at least two phys. sep. compns., of which one is a transdermal therapeutic system (TTS), containing the

dopaminergic agent and one or several other compns. containing the same dopaminergic agent and suitable for oral and/or parenteral administration. The compns. are suitable for the individually dosed and controlled treatment of dopaminergically treatable diseases with the following elements: (a) the TTS is continuously applied, (b) within the duration of application in (a) the composition for oral or parenteral dosage is administered. The preparation of transdermal patches is described along with the measurement of their percutan flux. Examples of tablets and parenteral compns. are given; the application to Parkinson's disease patent is reported.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:123600 CAPLUS
DOCUMENT NUMBER: 136:189348
TITLE: Inhibitors of monoamine oxidase used in combination with an addictive substance for substance addiction
INVENTOR(S): Biberman, Roni
PATENT ASSIGNEE(S): Israel
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20020019421	A1	20020214	US 2001-898027		20010705	<--
US 20020168403	A1	20021114	US 2002-86978		20020228	<--
PRIORITY APPLN. INFO.:			US 2000-216366P	P	20000705	
			US 2001-898027	A2	20010705	

AB Inhibitors of monoamine oxidase used in combination with an addictive substance, or a pharmacol. derivative or analog thereof, are useful for the treatment of substance addiction disorders. In particular, the invention discloses compns., and methods of use thereof, comprising selegiline and nicotine for the treatment of cigarette smokers wishing to abstain. The compns. and methods of use thereof include oral, inhalant, parenteral and transdermal patch modes of therapy, whereby the subject benefits from the combined effects of a monoamine oxidase inhibitor in combination with an addictive substance, or derivative thereof. Combination therapy with selegiline and nicotine was more effective than either drug alone.

L19 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:330972 CAPLUS
DOCUMENT NUMBER: 120:330972
ORIGINAL REFERENCE NO.: 120:58063a,58066a
TITLE: Disposition of 14C-quinelorane in dogs following oral or intravenous dosing and transdermal patch application
AUTHOR(S): Franklin, Ronald B.; Sittampalam, G. Sitta; Valia, Kirti H.; Quay, John F.
CORPORATE SOURCE: Dep. Drug Metab. Dispos., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SOURCE: Drug Development and Industrial Pharmacy (1994), 20(8), 1439-52
CODEN: DDIPD8; ISSN: 0363-9045
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A transdermal patch was developed to circumvent the emesis associated with the oral and i.v. administration of a dopamine agonist, quinelorane (I), to dogs. Approx. steady-state plasma concns. were achieved following the daily application of a transdermal patch for 7 days. Each dog received between 0.1 and 0.2 mg/kg per day from the transdermal patch. At steady-state conditions, dogs received either a single oral dose of 14C-I at 0.1 mg/kg, a bolus i.v. dose of 0.03 mg/kg or had a transdermal patch containing the radioactive free base, 14C-dI, applied to their abdomens for 24 h; the approx. dose was 0.18 mg/kg. The plasma pharmacokinetics were measured by liquid scintillation counting and ELISA. The systemic bioavailability of I, as measured by the ELISA, was 30%, indicative of first-pass metabolism The radioactive urinary metabolite profile was similar for all three routes of administration. Principal entities in the urine were I, the N-despropyl- and the hydroxy-lactam- metabolites, accounting for 29, 25 and 3% of the dose, resp. The major route of excretion of radioactivity was via the urine, irresp. of the route by which the drug was administerred.

L19 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:538502 CAPLUS
DOCUMENT NUMBER: 113:138502
ORIGINAL REFERENCE NO.: 113:23421a,23424a
TITLE: Transdermal delivery systems containing a dopamine agonist
INVENTOR(S): Bondi, Joseph V.; Loper, Alice E.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 344840	A2	19891206	EP 1989-201324	19890523 <--
EP 344840	A3	19900221		
R: CH, DE, FR, GB, IT, LI, NL				
JP 02237924	A	19900920	JP 1989-139367	19890602 <--
JP 05012330	B	19930217		

PRIORITY APPLN. INFO.: US 1988-202088 A 19880602
AB A transdermal delivery system for (4a-R-trans)-3,4,4a,5,6,10b-hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol (I), useful in the treatment of Parkinson's disease comprises (1) a backing member which is substantially impermeable to the drug, (2) a drug reservoir member consisting essentially of I and glycerol in a solid state matrix of cured silicone elastomer, (3) a rate-controlling membrane, and (4) an adhesive. The system delivers I at 2-20 μg/cm2/h to produce steady state plasma levels over an extended period of time. A dispersion of 2.13 g I and 21.34 g glycerol was mixed with 85.2g uncured silicone elastomer and dispensed between a cellulose triacetate backing sheet and a 1.5 mil polydimethylsiloxane rate-controlling membrane. The membrane-drug reservoir matrix assembly was hand-drawn and cured at 70° for 1.5h. An adhesive-coated impermeable backing was hand-laminated to the cured drug reservoir on the opposite side of the rate-controlling membrane and patches (5 cm2 in size) were die-cut from the laminated sheets. An in vitro diffusion rate of I was 18.6 μg/cm2/h.

=> d his

(FILE 'HOME' ENTERED AT 09:42:48 ON 05 AUG 2008)

FILE 'CAPLUS' ENTERED AT 09:45:03 ON 05 AUG 2008
E THEOBALD FRANK/AU 25

L1	30	S	(E3)
L2	14	S	L1 AND TRANSDERMAL
L3	0	S	L2 AND FLUX
L4	0	S	L2 AND "FLUX RATE"
L5	197	S	"TRANSDERMAL THERAPEUTIC SYSTEMS"
L6	0	S	L5 AND PRAMIPEXOL
L7	4	S	PRAMIPEXOL
L8	0	S	L5 AND PARKINSONS
L9	1309	S	"TRANSDERMAL PATCH"
L10	0	S	L9 AND PRAMIPEXOL
L11	0	S	L0 AND "ADHESIVE BACKING"
L12	54	S	L9 AND METHACRYLATE
L13	12	S	L12 AND "VINYL ACETATE"
L14	10	S	L13 AND ADHESIVE
L15	7	S	L9 AND "FLUX RATE"
L16	6224	S	"DOPAMINE AGONIST"
L17	16	S	L9 AND L16
L18	0	S	L17 AND @PY<=2003
L19	6	S	L17 AND PY<=2003